Cervical cancer is the third most common cancer among women worldwide and is responsible for
275.000 deaths each year. The development of cervical cancer has been linked to cell cycle disturbances caused
by persistent expression of high- risk HPV oncoproteins (E5, E6 and E7), which modulate the expression of
host genes and cellular microRNAs. An estimated 5 million women throughout the world are currently infected
by HPV and several of them will develop invasive cervical cancer. Despite failures in conventional screening tests, approved
therapies have no direct effect on HPV infection. In view of this, effective therapy for cervical cancer is still urgently
needed, particularly in developing countries where more than 85% of fatal cases occur. In this paper we review the
current molecular targeted therapies which are being explored and may have a significant impact on the treatment of
HPV- related cervical dysplasia and carcinoma.
Keywords: Cervical cancer, HPV, microRNA, molecular targets, therapy.
Rights & PermissionsPrintExport